GlassScriptPhysician profile
Elizabeth Clark
NPI 1316368848
$12,960.53
in general payments reported to CMS, 2019-2025
28 companies · $2,764 in 2025
The $2,764 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,800 · 2022: $2,351 · 2023: $2,717 · 2024: $2,328 · 2025: $2,764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,511 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,510.78 |
| Education | $297.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,858.23 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,748.03 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,328.19 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,176.25 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $922.93 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $739.88 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $681.29 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $613.98 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $578.60 | 2021-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $519.61 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $466.40 | 2021-2025 | Rexulti |
| Corium, LLC | $436.63 | 2022-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $420.97 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $243.52 | 2021-2022 | |
| Almatica Pharma LLC | $230.18 | 2021-2025 | Loreev Xr, Gralise |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $221.98 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $168.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $151.79 | 2022-2023 | Belsomra |
| Tris Pharma INC | $95.63 | 2023-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $82.15 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $71.03 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $39.59 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $37.81 | 2021 | |
| Noven Therapeutics, LLC | $34.89 | 2021-2023 | Xelstrym, Secuado |
| Validus Pharmaceuticals LLC | $34.45 | 2022-2023 | Equetro |
| Neos Therapeutics, LP | $26.33 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.68 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $13.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.